The COVID-19 Therapeutic Answer: vascoactive intestinal peptide Zyesami stops respiratory failure in patients with severe Covid with one dose.

https://finance.yahoo.com/news/nrx-pharmaceuticals-announces-finding-zyesami-120600828.html

Cardinal Health is new distributor for Zyesami

https://finance.yahoo.com/news/nrx-pharmaceuticals-cardinal-health-ensure-104800088.html ?

The FDA received the Zyesami EUA (emergency use authorization) application 93 days ago.

https://finance.yahoo.com/news/relief-therapeutics-reports-collaboration-partner-051000096.html

Zyesami stops the replication of the Covid virus and ALL variants, including the Delta and Lambda mutations. Zyesami stops the cytokine storm.

https://finance.yahoo.com/news/relief-reports-u-collaboration-partner-052000298.html

Zyesami now manufactured at a 30 to 50 fold increase in amount produced and at a 90% decrease in manufacturing cost.

https://finance.yahoo.com/news/nrx-pharmaceuticals-announces-first-successful-104800474.html

The nation of Georgia approved Zyesami EUA. 7-27-21

https://finance.yahoo.com/news/relief-reports-u-collaboration-partner-053000910.html5&amp

; Study of how Zyesami works.

https://youtu.be/EI4IpfmFfTg.

Dr. Joey Johnson More news:

https://finance.yahoo.com/news/mannkind-partners-nrx-pharmaceuticals-explore-104800970.html